Source comparison
Comparison: Sermorelin vs Other GH Protocols
Sermorelin 0.2–0.3 mg nightly GHRH receptor agonist. Stimulates endogenous GH pulse 200–280 ng/mL (upper normal) Minimal. Feedback loops preserved 6–24 months (cycled) Recombinant GH 2–4 IU daily Exogenous GH replacement. Bypasses pituitary 300–500+ ng/mL (sup
This comparison does not assign a generated winner or score.
- Sermorelin 0.2–0.3 mg nightly
- GHRH receptor agonist. Stimulates endogenous GH pulse
- 200–280 ng/mL (upper normal)
- Minimal. Feedback loops preserved
- 6–24 months (cycled)
- Recombinant GH 2–4 IU daily
- Exogenous GH replacement. Bypasses pituitary
- 300–500+ ng/mL (supraphysiological)
- High. Endogenous production suppressed 40–60%
- 3–6 months (medical supervision required)
- MK-677 (Ibutamoren) 25 mg daily
- Ghrelin receptor agonist. Constant GH elevation
- 250–350 ng/mL
- Moderate. Sustained elevation may desensitise
- 8–16 weeks (appetite side effects limit duration)
- CJC-1295 + Ipamorelin
- GHRH analog + GHRP. Dual pathway stimulation
- 220–300 ng/mL
- Low. Pulsatile release pattern maintained
- 12–24 weeks (commonly stacked)
- Sermorelin's safety advantage is its pharmacokinetic profile. The 8–10 minute half-life means plasma levels return to baseline within 60–90 minutes, allowing somatostatin to reassert control before the next dose. MK-677's 24-hour half-life creates sustained GH elevation that disrupts natural pulsatility. Exogenous GH remains elevated for 12+ hours depending on injection timing, completely overriding endogenous regulation.